Az Sint-Maarten

Mechelen 97770

5 studies enrolling now · 28 studies all time

What they study most

Acute Coronary Syndrome, Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Biliary Tract Neoplasms, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cardiovascular Disease, Chemotherapy-induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease, Colorectal Cancer, Covid-19

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Recruiting now
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting now
• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough — Running, not enrolling
• A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older — Completed
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) — Completed
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations — Running, not enrolling
• Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma — Stopped early
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis — Stopped early
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) — Stopped early
• Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults — Completed
• M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) — Completed
• Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients — Stopped early
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) — Stopped early
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early